<DOC>
	<DOCNO>NCT00642278</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness , safety , tolerability JNJ-28431754 compare placebo patient type 2 diabetes .</brief_summary>
	<brief_title>An Efficacy , Safety , Tolerability Study Canagliflozin ( JNJ-28431754 ) Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Type 2 diabetes mellitus metabolic disorder characterize decreased secretion insulin pancreas resistance action insulin various tissue ( muscle , liver , adipose ) , result impair glucose uptake . Chronic hyperglycemia lead progressive impairment insulin secretion insulin resistance peripheral tissue diabetes ( so-called glucose toxicity ) , worsen control blood glucose . In addition , chronic hyperglycemia major risk factor complication , include heart disease , retinopathy , nephropathy , neuropathy . Although numerous treatment develop treatment diabetes individual agent may highly effective patient , still difficult maintain optimal glycemic control patient diabetes . This randomized , double-blind , placebo-controlled , parallel group , multicenter , dose-ranging study determine efficacy , safety tolerability JNJ-28431754 take orally 12 week , compare placebo , treatment Type 2 diabetes mellitus . The primary clinical hypothesis JNJ-28431754 superior placebo measure change hemoglobin A1c baseline Week 12 treatment type 2 diabetes mellitus . Subject safety monitor throughout study use spontaneous adverse event reporting , clinical laboratory test ( hematology , serum chemistry , urinalysis ) ; severe serious hypoglycemic episode , assessment urinary albumin excretion marker proximal renal tubular function ; pregnancy test ; electrocardiogram ( ECGs ) ; vital sign measurement ; physical examination , assessment calcium phosphate homeostasis , bone formation resorption marker , hormone regulate calcium phosphorus homeostasis ; vaginal urine sample collection fungal bacterial culture subject symptoms consistent vulvovaginal candidiasis ( VVC ) urinary tract infection ( UTI ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Patients must diagnosis type 2 diabetes mellitus Hemoglobin A1c level &gt; =7 % &lt; =10.5 % take stable daily dose metformin Body mass index ( BMI ) 25 45 kg/m2 except Asian descent must BMI 24 45 kg/m2 Stable body weight Serum creatinine &lt; =1.5 mg/dL ( 132.6 umol/L ) men &lt; =1.4 mg/dL ( 123.76 umol/L ) woman Patients must prior exposure know contraindication suspect hypersensitivity canagliflozin ( JNJ28431754 ) Known contraindication suspect hypersensitivity sitagliptin metformin A history diabetic ketoacidosis type 1 diabetes mellitus History pancreas betacell transplantation History active proliferative diabetic retinopathy History hereditary glucosegalactose malabsorption primary renal glucosuria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Metformin</keyword>
	<keyword>Hemoglobin A1c</keyword>
</DOC>